Neurology:长期特发性REM睡眠行为障碍患者的特征

2017-06-16 zhangfan MedSci原创

长期原发性REM睡眠行为障碍患者均出现前驱帕金森病症状,这部分患者受到潜在神经退行性过程的影响,对出现长期原发性REM睡眠行为障碍患者应加强早期帕金森干预

近日研究人员探讨了帕金森病(PD)患者的早期特征之一--长期原发性REM睡眠行为障碍(IRBD)。长期随访发现,小部分的IRBD患者其发展为PD风险较高。

研究人员招募了20名多导睡眠图证实了长期IRBD患者以及32名对照志愿者对其进行帕金森人口学、临床和影像学标志物评估。

IRBD患者中,男性16人,女性4人,平均年龄72.9 ± 8.6岁,IRBD确诊后平均随访12.1 ± 2.6年。与对照志愿者相比,IRBD患者更频繁出现以下症状:嗅觉丧失((35% vs 3.4%)、便秘(50% vs 15.6%)和中度帕金森样症状(45% vs 18.8%)。IRBD患者在统一的帕金森病运动评分中的分数更高(5.6 ± 3.5 vs 2.0 ± 2.1,p < 0.0001)。多巴胺转运蛋白显像显示患者纹状体摄取减少82.4%,经颅超声发现黑质回声增强35.3%。对6名患者进行结肠或颌下腺活检发现,其中3人存在α-突触核蛋白聚集。所有20例患者均显示帕金森病的临床、影像学或组织学标志物。IRBD患者前驱PD概率高于对照组(P< 0.0001),45%的患者概率超过80%。

研究认为,长期原发性REM睡眠行为障碍患者均出现前驱帕金森病症状,这部分患者受到潜在神经退行性过程的影响,对出现长期原发性REM睡眠行为障碍患者应加强早期帕金森干预。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1709762, encodeId=83241e0976232, content=<a href='/topic/show?id=3c0e90045ac' target=_blank style='color:#2F92EE;'>#行为障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90045, encryptionId=3c0e90045ac, topicName=行为障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=895a31785550, createdName=12498cb5m23暂无昵称, createdTime=Thu May 17 20:33:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752229, encodeId=7a821e52229eb, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Thu Nov 02 09:33:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894606, encodeId=102a189460600, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Mon Apr 23 12:33:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999988, encodeId=08111999988a7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Oct 21 08:33:00 CST 2017, time=2017-10-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1709762, encodeId=83241e0976232, content=<a href='/topic/show?id=3c0e90045ac' target=_blank style='color:#2F92EE;'>#行为障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90045, encryptionId=3c0e90045ac, topicName=行为障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=895a31785550, createdName=12498cb5m23暂无昵称, createdTime=Thu May 17 20:33:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752229, encodeId=7a821e52229eb, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Thu Nov 02 09:33:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894606, encodeId=102a189460600, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Mon Apr 23 12:33:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999988, encodeId=08111999988a7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Oct 21 08:33:00 CST 2017, time=2017-10-21, status=1, ipAttribution=)]
    2017-11-02 tongyongming
  3. [GetPortalCommentsPageByObjectIdResponse(id=1709762, encodeId=83241e0976232, content=<a href='/topic/show?id=3c0e90045ac' target=_blank style='color:#2F92EE;'>#行为障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90045, encryptionId=3c0e90045ac, topicName=行为障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=895a31785550, createdName=12498cb5m23暂无昵称, createdTime=Thu May 17 20:33:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752229, encodeId=7a821e52229eb, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Thu Nov 02 09:33:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894606, encodeId=102a189460600, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Mon Apr 23 12:33:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999988, encodeId=08111999988a7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Oct 21 08:33:00 CST 2017, time=2017-10-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1709762, encodeId=83241e0976232, content=<a href='/topic/show?id=3c0e90045ac' target=_blank style='color:#2F92EE;'>#行为障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90045, encryptionId=3c0e90045ac, topicName=行为障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=895a31785550, createdName=12498cb5m23暂无昵称, createdTime=Thu May 17 20:33:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752229, encodeId=7a821e52229eb, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Thu Nov 02 09:33:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894606, encodeId=102a189460600, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Mon Apr 23 12:33:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999988, encodeId=08111999988a7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Oct 21 08:33:00 CST 2017, time=2017-10-21, status=1, ipAttribution=)]
    2017-10-21 yinhl1978

相关资讯

JAMA Neurol:金刚烷胺缓释剂用于帕金森患者左旋多巴诱发异动症

睡前274mg的ADS-5102可以有效的治疗左旋多巴诱发异动症并减少左旋多巴导致的运动症状持续时间

Neurology:帕金森运动障碍类型的基线预测

大部分帕金森患者基线运动障碍特征可预测其疾病进展导致的运动障碍,该研究对帕金森的临床治疗具有一定的指导作用

Neurology:乳制品摄入与帕金森风险

乳制品的频繁摄入可导致中度的帕金森病风险增加

JAMA Neurol:气味识别试验与多巴胺转运体显像用于帕金森早期诊断

嗅觉测试联合多巴胺转运体显像对于4年内帕金森患者的确诊具有较高的预测率,嗅觉异常伴多巴胺转运体显像缺失的患者每年会减少5%的多巴胺转运体,表现出早期帕金森症状。该研究对于帕金森的早期检测和治疗具有重要意义

首例胚胎干细胞临床试验 中国医学的里程碑

一直以来,胚胎干细胞(ES细胞)疗法在中国广受争议。在2015年ES细胞研究规则未落实之前,中国没有明确的监管措施,许多公司将此作为借口推销未经证实的干细胞治疗。5月底,对于中国首例使用人类ES细胞的临床试验,《Nature》杂志网站以正面的态度进行了报道和评价。

Cell:“升级版”TMS有望治疗帕金森等多种神经疾病

去年年底,麻省理工学院(MIT)的神经科学家蔡立慧(Li-Huei Tsai)领导的研究小组在Nature上发表的一项研究引起广泛关注,他们利用特定频率闪烁的LED灯,大大减少了阿尔茨海默病模型小鼠大脑中的β-淀粉样蛋白斑,这种无创、容易开展的方法为阿尔茨海默病的治疗开辟了一个新方向。近日,该研究小组与MIT的同事和贝斯以色列女执事医疗中心(BIDMC)的研究人员合作,在Cell上又发表了一项可能